BRAF and neoplasm: To explore the potential anti-tumor targets of apatinib, we have examined all tyrosine kinases and important silk/threonine kinases associated with lung cancer including Akt 1-3, FRAP1, PIK3C2A, PIK3C2B, BRAF, BRAF V600E and RAF1 in the Life platform [21].